SI
UTHR icon

Stirlingshire Investments’s United Therapeutics UTHR Stock Holding History

Stirlingshire Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$495K Buy
913
+393
+76% +$221K 0.37% 89
2026
Q1 		$308K Buy
520
+36
+7% +$17.9K 0.27% 109
2025
Q4 		$236K Buy
+484
New +$225K 0.21% 158

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Stirlingshire Investments's UTHR Position: Q2 2026 in Review

Stirlingshire Investments increased its United Therapeutics (UTHR) stake by 76% in Q2 2026, buying an estimated $221K and bringing the position to 913 shares worth $495K. The position accounts for 0.37% of the portfolio, ranked #89.

Stirlingshire Investments first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Stirlingshire Investments held 913 shares of United Therapeutics worth $495K as of Q2 2026.
  • Stirlingshire Investments bought 393 United Therapeutics shares in Q2 2026, an estimated $221K.
  • United Therapeutics made up 0.37% of Stirlingshire Investments's portfolio in Q2 2026, its #89 holding.
  • Stirlingshire Investments first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Stirlingshire Investments's 13F filing for Q2 2026, filed 31 Jul 2026.